Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02730312 | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies | PHASE1 | COMPLETED | 120 | — | — | Aug 1, 2016 | Sep 1, 2021 | Mar 8, 2022 | 9 | United States |
Treatment-related adverse events as assessed by CTCAE v4.03
| Arm | Type | Description |
|---|---|---|
| XmAb14045 | EXPERIMENTAL | Biological/Vaccine: XmAb14045 Administered IV weekly up to 8 weeks |
| Name | Type | Description |
|---|---|---|
| XmAb14045 | BIOLOGICAL | Administered IV weekly up to 8 weeks, with or without step-up dosing |
Inclusion Criteria: * Diagnosis of 1 of the following diseases: * Primary or secondary AML (including erythroleukemia and eosinophilic leukemia, but excluding acute promyelocytic leukemia) * B-cell ALL * BPDCN * CML in blast phase, resistant or intolerant to tyrosine kinase inhibitor thera...